Chardan Capital Reaffirms “Sell” Rating for Regeneron Pharmaceuticals Inc. (REGN)
Chardan Capital reaffirmed their sell rating on shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) in a research report report published on Friday. Chardan Capital currently has a $325.00 price objective on the biopharmaceutical company’s stock.
“We believe the news is an important long-term negative, as REGN (Sell, PT$325) is increasingly exposed to what we expect could be a 2017+ theme in wet AMD of treatment burden reduction.”,” the firm’s analyst wrote.
Several other research analysts also recently commented on the company. Goldman Sachs Group Inc. reissued a buy rating and issued a $521.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 27th. Jefferies Group reissued a hold rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, August 17th. Vetr downgraded Regeneron Pharmaceuticals from a strong-buy rating to a buy rating and set a $419.76 target price on the stock. in a report on Monday, July 11th. Zacks Investment Research raised Regeneron Pharmaceuticals from a hold rating to a buy rating and set a $472.00 target price on the stock in a report on Tuesday, August 9th. Finally, Leerink Swann reissued a buy rating and issued a $530.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, September 21st. One investment analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average target price of $480.09.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 397.20 on Friday. The stock has a 50 day moving average price of $403.67 and a 200 day moving average price of $391.72. The firm has a market cap of $41.56 billion, a PE ratio of 61.97 and a beta of 1.31. Regeneron Pharmaceuticals has a 12 month low of $329.09 and a 12 month high of $592.59.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.65 by $0.17. The business had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a return on equity of 23.77% and a net margin of 15.65%. Regeneron Pharmaceuticals’s revenue was up 21.4% compared to the same quarter last year. During the same period in the previous year, the business earned $2.89 EPS. On average, equities research analysts expect that Regeneron Pharmaceuticals will post $11.00 EPS for the current year.
In other news, Director Joseph L. Goldstein sold 2,125 shares of the stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the transaction, the director now directly owns 15,125 shares in the company, valued at approximately $6,428,125. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 10.40% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. FMR LLC increased its position in Regeneron Pharmaceuticals by 9.2% in the second quarter. FMR LLC now owns 9,416,836 shares of the biopharmaceutical company’s stock worth $3,288,642,000 after buying an additional 795,283 shares in the last quarter. Capital World Investors boosted its stake in shares of Regeneron Pharmaceuticals by 4.4% in the second quarter. Capital World Investors now owns 7,326,626 shares of the biopharmaceutical company’s stock worth $2,558,678,000 after buying an additional 312,008 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Regeneron Pharmaceuticals by 29.8% in the first quarter. Wellington Management Group LLP now owns 6,212,394 shares of the biopharmaceutical company’s stock worth $2,239,195,000 after buying an additional 1,426,801 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 4,779,186 shares of the biopharmaceutical company’s stock worth $1,669,035,000 after buying an additional 92,467 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 0.5% in the second quarter. State Street Corp now owns 3,093,295 shares of the biopharmaceutical company’s stock worth $1,080,272,000 after buying an additional 15,272 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.